Completed PHASE3 INTERVENTIONAL 3-arm NCT01397461

Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

A Phase III 3 Arms, Multicenter, Randomised, Investigator-blind Study to Assess the Efficacy and Safety of Ozenoxacin 1% Cream Applied Twice Daily for 5 Days Versus Placebo in the Treatment of Patients With Impetigo

Sponsor: Ferrer Internacional S.A.

Conditions Impetigo

Interventions ozenoxacin 1% cream ozenoxacin placebo retapamulin 1% ointment

Updated 7 times since 2017 Last updated: Jun 1, 2016 Started: Mar 31, 2012 Primary completion: Dec 31, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Impetigo, this trial is completed. The trial is conducted by Ferrer Internacional S.A. and has accumulated 7 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ferrer Internacional S.A.

Data source: Ferrer Internacional S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Augsburg, Germany , Benoni, South Africa , Bloemfontein, South Africa , Cologne, Germany , Dresden, Germany , Dundee, South Africa , Frankfurt am Main, Germany , George, South Africa , Hatfield, South Africa , Johannesburg, South Africa and 8 more locations